Repolar Ltd.   Report issue

For profit Phase 4
Founded: Espoo Finland (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2013
NCT01851590
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (3)

Amorolfine (loceryl) (1 trial)

resin (1 trial)

terbinafine (lamisil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Onychomycosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 3